

# Assessing the accuracy of routinely collected data and their potential use in pressure ulcer trials


## Background

In the absence of electronic records, current adverse event (AE) reporting relies on staff reporting an AE to an electronic system; for pressure ulcer monitoring, systems have been introduced in the English NHS including;

- Safety Thermometer (STh)
- Incident Reporting Systems (IRS) (e.g. Datix/Ulysses)
- Strategic Executive Information System (STEIS) for the reporting of Serious Incidents Requiring Investigation (SIRI).

Wealth of routinely collected pressure ulcer data that could theoretically be utilised for pressure ulcer research.

Concerns about inconsistencies in the local implementation of these systems and over-interpretation of data, prompted the Tissue Viability Society (TVS) to fund a project, supported by NHS England, to assess the accuracy of pressure ulcer monitoring in England.



## Project Design

### Gold Standard:

Audit conducted in line with 'gold standard' pressure ulcer prevalence methods



### Sample:

Stratified random sample of Trusts

### Stratification factors:

- Geographical location (North/South)
- Size of Trust (Small/Medium/Large based on number of beds)
- STh Outlier status in May 2014 (Low outlier/Normal/High outlier)

A qualitative survey was also conducted to elicit information about local practice and implementation of monitoring systems



## Sample size

Based on patient level data to ensure a direct comparison of the STh data with the audit data

### Assumptions:

- Prevalence of Category 2 and above Pressure ulcers of 6.3% [1]
- Sensitivity of 70% based on local audit work in one Trust
- 5% significance level
- No drop out

Sample size of 2614 evaluable patients required to estimate STh submission sensitivity and specificity with 95% confidence intervals of widths +/- 7% and +/- 0.02%, respectively.

## Analysis

Weighted sensitivity and specificity were estimated using Safety Thermometer data provided by NHS England. An example of the method for calculating sensitivity is provided here using Begg and Greene's paper [2]. Let

$$R = \begin{cases} 1, & \text{If on the Safety Thermometer} \\ 0, & \text{Otherwise} \end{cases}$$

$$D = \begin{cases} 1, & \text{If patient has a PU on the wound audit} \\ 0, & \text{Otherwise} \end{cases}$$

$$V = \begin{cases} 1, & \text{If patient was assessed in the TVS audit} \\ 0, & \text{Otherwise} \end{cases}$$

$X =$  strata with the number of strata ranging from  $i = 1$  to  $i = 18$

	From stratified random sample			From the NHS data (i.e. sampling frame)		
	$D = 1$	$D = 0$		$R = 1$	$R = 0$	
$R = 1$	$a_i$	$b_i$	$a_i + b_i$	$e_i$		
$R = 0$	$c_i$	$d_i$	$c_i + d_i$	$f_i$		
	$a_i + c_i$	$b_i + d_i$		$e_i + f_i$		

Then for each strata,  $i$ , we have:

$$\text{Let } T = \sum_{i=1}^{18} (e_i + f_i).$$

Assuming that participant selection does not depend on disease status we have, from

$$\text{Bayes Theorem: Sensitivity} = Pr(R = 1 | D = 1) = \frac{\sum_{i=1}^{18} \left( \frac{e_i a_i}{a_i + b_i} \right)}{\sum_{i=1}^{18} \left( \frac{e_i a_i}{a_i + b_i} + \frac{f_i c_i}{c_i + d_i} \right)}$$

Note that if our sample was the same as our entire sampling frame then  $e_i = a_i + b_i$  and

$f_i = c_i + d_i$  which reduces our sensitivity calculation down to  $\frac{\sum_{i=1}^{18} a_i}{\sum_{i=1}^{18} (a_i + c_i)} = \frac{A}{A+C}$  (i.e.

unweighted sensitivity)

The data provided by the NHS has the following structure:

Therefore, for each strata,  $i$ ,  $e_i = \sum_j q_j m_j$  and  $f_i = \sum_j (m_j - q_j m_j)$  where  $j$  corresponds to Trust.

Strata	Trust	PU prevalence (according to STh)	No. of beds
1	1	$q_1$	$m_1$
1	2	$q_2$	$m_2$
1	3	$q_3$	$m_3$
2	4	$q_4$	$m_4$
2	5	$q_5$	$m_5$
3	6	$q_6$	$m_6$
3	7	$q_7$	$m_7$

## Results

- Data was received for 2239 patients, from 24 NHS Trusts providing in-patient services for adult populations in England.
- Weighted prevalence of existing pressure ulcers was 6.6% (95% CI 5.3% to 8.0%)

Reporting System	Sensitivity (95% CI)	Specificity (95% CI)
STh (weighted estimates)	48.2% (35.4%-56.7%)	99.0% (99.0%-99.0%)
IRS (unweighted estimates)	53.4% (46.3% to 60.4%)	98.3% (97.7% to 98.8%)

- Of the 2239 patients 83 had one or more potentially serious pressure ulcer and 8 (9.6%) were reported on STEIS.

## Discussion

Using a robust methodological approach we undertook an audit and survey to compare current data sources including in-patient STh data, IRS and STEIS. Two key findings were:

- High levels of under-reporting for all systems
- The adoption of different definitions and variation in data collection and validation processes which preclude Trust-to-Trust comparisons of pressure ulcer prevalence and incident rates.

This indicates that, at present, *current routine data sources for pressure ulcer monitoring are inadequate for identifying outcomes in pressure ulcer research.*

The results add to the wider international debate relating to the use of adverse event metrics data to assess improvement in patient safety and reductions in patient harms [3].

We did not assess the accuracy of individual patient level notes; further work is required to assess the reliability of hand written records and/or accuracy of electronic records when they are introduced more widely in the NHS

## References

1. Briggs, M., et al., *The prevalence of pain at pressure areas and pressure ulcers in hospitalised patients* <http://www.biomedcentral.com/1472-6955/12/19>. BMC Nurs, 2013. 12(1): p. 19.
2. Begg, C.B. and R.A. Greenes, *Assessment of diagnostic tests when disease verification is subject to selection bias*. Biometrics, 1983. 39(1): p. 207-15.
3. Shojania, K.G. and P.J. Marang-van de Mheen, *Temporal trends in patient safety in the Netherlands: reductions in preventable adverse events or the end of adverse events as a useful metric?* BMJ Quality & Safety, 2015

## Acknowledgements

- NHS England's Patient Safety Domain
  - NHS England - North (Yorkshire & the Humber) Pressure Ulcer Safeguarding Professional Reference Group
  - The 24 participating NHS Trusts and their staff
  - Val Henderson, Clinical Lead Tissue Viability, Northumbria Healthcare Foundation Trust
  - Margaret Broome, Wound Care Research Nurse, Harrogate and District NHS Foundation Trust
  - Tracy Vernon, Lead Nurse - Tissue Viability, Doncaster & Bassetlaw Hospitals NHS Foundation Trust
  - CTRU team: Prof. Linda Sharples, Howard Collier, Chris Taylor, Abigail Ledger
- This publication presents independent research funded by the Tissue Viability Society. The views expressed in this publication are those of the author(s) and not necessarily those of the Tissue Viability Society.